New Pharmaceuticals market report from GlobalData: "PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022"
Boston, MA -- (SBWIRE) -- 03/18/2013 -- GlobalData has released its new Country report, "PharmaPoint: Epilepsy - Spain Drug Forecast and Market Analysis to 2022". Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal. Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period. Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market. However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
View Full Report Details and Table of Contents
The main drivers for growth in this market are the launch of new AEDs, the continued uptake of recent AEDs, and the lower-than-average rate of generic substitution in Spain compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.
Report Scope
- Overview of Epilepsy including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Spain Epilesy market.
Reasons to Get this Report
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Epilepsy
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Spain
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- PharmaPoint: Epilepsy - Japan Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - France Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - US Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - UK Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - India Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - Germany Drug Forecast and Market Analysis to 2022
- PharmaPoint: Epilepsy - China Drug Forecast and Market Analysis to 2022
- PharmaPoint: Prostate Cancer - United States Drug Forecast and Market Analysis to 2022
- PharmaPoint: Prostate Cancer - Italy Drug Forecast and Market Analysis to 2022